Description
Active Ingredient
This medication contains the main active ingredient Abiraterone Acetate. This component is a sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. It is used for the treatment of metastatic castrate-resistant prostate cancer. It plays as a role of a prodrug, an antineoplastic agent, and steroid alpha-monooxygenase inhibitor. The drug is a member of pyridines, which is derived from an abiraterone.
It shows antiandrogen activity, which inhibits the enzymatic activity of steroid alpha-monooxygenase, a member of the cytochrome that catalyzes the alpha-hydroxylation of steroid intermediates. It is involved in testosterone synthesis.
Indications
The medication is used in combination with the steroid prednisone for the treatment of a certain type of late-stage prostate cancer in men. Especially in men who have already been treated with chemotherapy. The mentioned medicine is approved for the treatment of Metastatic castration-resistant prostate cancer (CRPC)and Metastatic high-risk castration-sensitive prostate cancer (CSPC).
Action Mechanism
This conventional tablet Zytiga targets a protein called CYP17A1, which plays a key role in the production of testosterone. It works by reducing the production of testosterone that stimulates cancer cells to keep growing.
Dosages
The given medicine Zytiga is approved for the treatment of prostate cancer in men. It is available in dosages as mentioned below:
- 250 mg: The pill is usually taken once per day with or without food. Follow the doctor’s dosing instructions very carefully
Note
This medication should not be handled by the pregnant woman. It is not approved for use by anyone younger than 18 years old.
Reviews
There are no reviews yet.